Chemical Namevoxelotor
Dosage FormTablet (oral; 500 mg); Tablet for oral suspension (oral; 300 mg)
Drug ClassInhibitors
CompanyGlobal Blood Therapeutics
Approval Year2019


  • For the treatment of sickle cell disease in adults and pediatric patients 4 years of age and older
Last updated on 4/8/2022

More on this drug: Clinical Trials

Document TitleYearSource
Oxbryta (voxelotor) Prescribing Information.2019Global Blood Therapeutics

Have we missed a study, or would you like to comment on a study?